Glenn Noronha has 20 years of progressive leadership positions in large, medium and small pharma/biotech companies including three start-ups with experiences that span end-to-end development including drug approval, post-approval, and clinical & translational efforts in ophthalmology, oncology & GI diseases. Glenn came to BridgeBio from Clearside Biomedical, Inc. where he headed clinical and regulatory strategy and development and was CSO. He was responsible for the strategy and execution of development from the late preclinical stage through Phase 1 through Phase 3 trials, with efforts that resulted in an NDA. In addition, he was one of the three executives who took Clearside public in 2016. Prior to that he was at Sucampo and at JW Therapeutics as Head of R&D and CSO. His Ophthalmology development experiences include being Global lead for Retina development at Alcon and work with Novartis Ophthalmology after the acquisition. He led 6 programs from the candidate nomination stage through clinical development and approval. Prior to that he was co-lead for Ophthalmology development at TargeGen. His experience includes small molecules and biologics as well as gene therapy. He has worked in macular degeneration, diabetic retinopathy, venous occlusive disease, and uveitis. His efforts have resulted in 4 approved drugs. He has deep experience with the FDA, the EMA, the PMDA, the DCGI, and other health authorities, regulatory bodies and ethics committees.